Drug Maker To Pay Over $21M To Settle Foreign Corruption Practices Violations
WASHINGTON, D.C. — A pharmaceutical company will pay more than $21 million to settle claims brought by the Securities and Exchange Commission that allege that the defendant violated provisions of the...To view the full article, register now.
Already a subscriber? Click here to view full article